<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://newzino.com/story/qxo-topbuild-acquisition-2026</loc>
    <news:news>
      <news:publication>
        <news:name>Newzino</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-04-20T03:05:52+00:00</news:publication_date>
      <news:title>Brad Jacobs assembles $30 billion building products empire in two years</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://newzino.com/story/blue-origin-new-glenn-reusability</loc>
    <news:news>
      <news:publication>
        <news:name>Newzino</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-04-19T18:09:49+00:00</news:publication_date>
      <news:title>Blue Origin proves New Glenn booster reuse, enters the reusable heavy-lift race</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://newzino.com/story/psychedelic-therapy-federal-policy</loc>
    <news:news>
      <news:publication>
        <news:name>Newzino</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-04-18T15:09:45+00:00</news:publication_date>
      <news:title>Federal psychedelic therapy policy shifts from prohibition to expedited research</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://newzino.com/story/obesity-drug-development-glp1</loc>
    <news:news>
      <news:publication>
        <news:name>Newzino</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-04-18T11:09:44+00:00</news:publication_date>
      <news:title>The race to build the next generation of weight-loss drugs</news:title>
    </news:news>
  </url>
</urlset>